Cancer Immunology, Immunotherapy : Impact Factor & More
eISSN: 1432-0851pISSN: 0340-7004
Share this on:
Key Metrics
CiteScore 
10
Impact Factor
5 - 10
SNIP
1.25
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Cancer Immunology, Immunotherapy Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
SJR
| Overview | |
| Publisher | SPRINGER |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1976 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Cancer Immunology, Immunotherapy ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Cancer Immunology, Immunotherapy
CD39/CD73-mediated immunosuppression and tumor aggressiveness in bladder cancer.
- 22 Apr 2026
- Cancer immunology, immunotherapy : CII
Neutral sphingomyelinases restrict natural killer cells activity against lung cancer.
- 22 Apr 2026
- Cancer immunology, immunotherapy : CII
Repurposing public sarcoma multi-omics for neoantigen discovery.
- 21 Apr 2026
- Cancer immunology, immunotherapy : CII
IL-18-armed oncolytic vaccinia virus remodels the suppressive microenvironment via macrophage and Treg modulation in lymphoma.
- 21 Apr 2026
- Cancer immunology, immunotherapy : CII
Identification and prioritisation of tumour antigen candidates from 79 glioblastoma transcriptomes.
- 21 Apr 2026
- Cancer immunology, immunotherapy : CII
Envafolimab combined with lenvatinib and albumin-bound paclitaxel in previously treated advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: a prospective, phase II, multi-cohort trial.
- 21 Apr 2026
- Cancer immunology, immunotherapy : CII
CD39/CD73-mediated immunosuppression and tumor aggressiveness in bladder cancer.
- 22 Apr 2026
- Cancer immunology, immunotherapy : CII
Neutral sphingomyelinases restrict natural killer cells activity against lung cancer.
- 22 Apr 2026
- Cancer immunology, immunotherapy : CII
Repurposing public sarcoma multi-omics for neoantigen discovery.
- 21 Apr 2026
- Cancer immunology, immunotherapy : CII
IL-18-armed oncolytic vaccinia virus remodels the suppressive microenvironment via macrophage and Treg modulation in lymphoma.
- 21 Apr 2026
- Cancer immunology, immunotherapy : CII
Identification and prioritisation of tumour antigen candidates from 79 glioblastoma transcriptomes.
- 21 Apr 2026
- Cancer immunology, immunotherapy : CII
Envafolimab combined with lenvatinib and albumin-bound paclitaxel in previously treated advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: a prospective, phase II, multi-cohort trial.
- 21 Apr 2026
- Cancer immunology, immunotherapy : CII
FAQs on Cancer Immunology, Immunotherapy
How long has Cancer Immunology, Immunotherapy been actively publishing? 
What is the publishing frequency of Cancer Immunology, Immunotherapy?
How many articles did Cancer Immunology, Immunotherapy publish last year?
What is the eISSN & pISSN for Cancer Immunology, Immunotherapy?
What is Citescore for Cancer Immunology, Immunotherapy?
What is SNIP score for Cancer Immunology, Immunotherapy?
Who is the publisher of Cancer Immunology, Immunotherapy?
